Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Key months ahead for Nanobiotix as trial data comes through

Data from the European head and neck trial with lead product NBTXR3 will be presented at the ASCO meeting in June
picture of Paris
Nanobiotix is based n the French capital

Euronext-listed Nanobiotix (EPA:NANO) has stepped up the pace of its phase I/II head and neck cancer trial to get the results back in time for the American Society of Clinical Oncology (ASCO) annual meeting.

Data from the European head and neck trial with lead product NBTXR3 will be presented at the ASCO meeting ahead of the next stage of clinical trials, which will be influenced by the data to be presented in June.

In addition, Nanobiotix is to expand its Immuno-Oncology program that aims to turn ‘cold tumours’ into ‘hot tumours’, which can then be recognised and attacked by the body’s immune system.

 

Hafnium oxide nanoparticles

The Paris-based group is pioneering the use of hafnium oxide nanoparticles to boost the effectiveness of radiotherapy.

Using its technology, radiotherapy doses are targeted much more precisely, reducing the damage to surrounding healthy tissue and shrinking tumours so they can be more easily removed by surgery.

NBTX R3, the most advanced product, is currently being tested in indications accessible to intra-tumour injections such as liver, prostate cancers as well as head & neck and soft tissue sarcomas.

Nanobiotix will present the first clinical data from the immune-oncology program mid-year having started an exploratory clinical biomarkers study using data from its phase II/III trial in soft tissues sarcoma.

This phase II/IIItrial is ongoing, having just been recommended to continue by an Independent Data Monitoring Committee (IDMC) that evaluated the safety and efficacy data of two thirds of the patients in the “Act.in.Sarc” study.

The completion of the patient recruitment process for this trial is expected by the end of the second quarter of 2017 with data expected by the end of the year.

 Other trials underway for NBTXR3 in other indications include prostate cancer (Phase I/II), liver cancers (Hepatocellular Phase I/II and liver cancer metastases Phase I/II), rectum cancer (Phase I/II – by partner PharmaEngine) and head and neck cancers in patients receiving chemotherapy (Phase I/II – by PharmaEngine).

 

Results due

In the second half of 2017, the prostate cancer indication should deliver preliminary safety and feasibility data.

Additionally, before the end of 2017, Nanobiotix aims to complete patient recruitment for the Phase I in liver cancers, and may proceed to select the patient population for the dose-expansion part of the trial (Phase II).  

In parallel, Nanobiotix is accelerating its market preparations for NBTXR3’s launch on the European market. The first approval (CE marking) in Europe is expected in the second half of 2017.

 

Undervalued believes Bryan Garnier

The French broker has started coverage of the nanotechnology pioneer with a buy recommendation and target price for the Euronext-listed shares of €35. That compares to €16.80 currently.

The current RTx market is already sizeable (50-60% of cancer patients are already treated with this modality) says Bryan Garnier, but it believes that Nanobiotix should not only occupy a privileged position in it, but can also contribute to its expansion in two phases.

“Firstly, by demonstrating a significant therapeutic benefit in indications where RTx is little used for the moment (like liver cancers).

“Then, in view of the multiple synergies between its platform and agents destined for treatment of more advanced tumours/metastasis, such as immunotherapies and a number of targeted new therapies (in particular PARP inhibitors). “

 

 

View full NANO profile View Profile

Nanobiotix SA Timeline

Related Articles

Cancer highlighted
July 10 2017
The collaboration will see PDS Biotechnology Corp and a subsidiary of Merck & Co Inc embark on a new clinical trial collaboration for metastatic head and neck cancer
newspaper with word cancer magnified
July 11 2017
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently
test tubes in a laboratory
November 01 2017
If you’re a pharmacist looking to get your hands on an unlicensed drug, there’s a good chance Clinigen can help

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use